This study investigated the associations of sFLC κ, λ and the κ/λ ratio with clinical features, cytogenetic abnormalities, prognosis and response to the VRd regimen (bortezomib, lenalidomide, dexamethasone) in newly diagnosed MM (NDMM) patients, aiming to optimize risk stratification. In conclusion, abnormal sFLC κ is a potential marker of poor prognosis and suboptimal response to VRd therapy in NDMM. Integrating sFLC κ with the R-ISS improves risk stratification, providing new evidence for clinical application of this biomarker.

Notably, L5 showed superior potency in MCF-7 cells with IC50; 1.16 µM compared to the FDA-approved thiosemicarbazone Triapine with IC50; 4.27 µM, while displaying minimal toxicity toward non-tumorigenic MCF-10a breast epithelial cells with selectivity index > 86.20, consistent with ADMET predictions. Molecular docking and molecular dynamics simulations demonstrated stronger binding affinity and greater complex stability of L5 with PTOV1 compared to the FDA approved drug Lenalidomide, supporting L5 drug likeness and therapeutic potential...L5 enhanced H2AX phosphorylation, suppressed PARP and BCL-XL levels, and increased active caspase-3 driving L5 induced apoptosis. This study identifies L5 as a potent anticancer agent in breast cancer, acting through modulation of the PTOV1-AKT-β-catenin signaling axis, and highlights PTOV1 as a promising therapeutic target.

P2, N=10, Completed, Ciusss de L'Est de l'Île de Montréal | Active, not recruiting --> Completed

P1/2, N=32, Active, not recruiting, University of Aarhus | Recruiting --> Active, not recruiting | Trial completion date: Mar 2026 --> Mar 2027 | Trial primary completion date: Mar 2026 --> Mar 2027

Utilizing this workflow, we studied dose-dependent protein degradation patterns induced by pomalidomide, iberdomide, and mezigdomide. Our results indicate that mezigdomide may possess enhanced efficacy in T cells by degrading additional proteins such as IKZF2, thereby boosting anticancer immunity. Together, we developed an ultrahigh-throughput LC-MS/MS method with excellent proteome coverage and quantitation accuracy that is highly suitable for chemoproteomics screening of drug libraries.

PROTAC LNPs were synthesized by modifying F1324 and pomalidomide aptamers onto LNPs via a covalent chemical reaction in a certain proportion...Overall, we developed a PROTAC that exhibited persistent and excellent BCL6 degradation ability in DLBCL, with an excellent safety profile. Thus, our BCL6 degrader provides a complementary approach to existing clinical‑stage candidates.

P2/3, N=2310, Recruiting, CSL Behring | Trial completion date: Sep 2029 --> May 2029 | Trial primary completion date: Sep 2029 --> May 2029

P2, N=31, Recruiting, The First Affiliated Hospital of Soochow University | Trial completion date: Dec 2023 --> Jun 2026

P3, N=10000, Recruiting, Novo Nordisk A/S | N=3884 --> 10000

P3, N=460, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Feb 2026 --> Mar 2027

P3, N=306, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Feb 2026 --> Feb 2027

P3, N=226, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2026 --> Mar 2027